News
Barchart on MSN3d
What You Need To Know Ahead of Merck's Earnings ReleaseMerck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.
Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.
Verona Pharma, a year after receiving regulatory approval for its landmark chronic obstructive pulmonary disease (COPD) treatment, is being acquired by pharmaceutical giant Merck in a deal worth about ...
In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Merck & Company. The company’s shares closed yesterday at $81.37. Don’t Miss TipRanks ...
Global markets have been seesawing this week, as traders digest the latest trade tariff news. Overnight, Asia-Pacific markets ...
Zacks.com on MSN3d
Merck Faces Multiple Challenges: Will It Steer Through Successfully?Though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then. Merck remains heavily dependent on Keytruda for growth. Our model estimate for Keytruda ...
Stocks are slightly higher on Wall Street as the Trump administration seeks to win more deals with global trading partners.
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback